Search - Prime Therapeutics - Portal

472 Results for GLP-1 Pipeline Update

Business Insider: Inside your company's struggle over whether to pay for hot, new weight-loss drugs

Business Insider

PA Sub-Categories: GLP-1 Prime Article: In the News
Endpoint News: Almost all patients quit weight loss shots within two years, analysis finds

Endpoint News

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Weight-loss drugs didn't curb health costs within two years

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
Washington Post: Weight-loss drugs are supposed to be forever. Until they run out.

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: Most patients stop using Wegovy, Ozempic for weight loss within two years

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News
NBC News: Most people stop using Wegovy and Ozempic after 2 years, analysis finds

NBC News: Patients weren't asked why they quit taking the weight loss drugs

PA Sub-Categories: GLP-1 Prime Article: In the News
Reuters: Exclusive: New data show most US patients now stay on Wegovy, Zepbound after a year

Reuters

PA Sub-Categories: GLP-1 Prime Article: In the News

Login Portals

Compliance / Legal

Company

© 2026 Prime Therapeutics LLC